Dmitry Bentsion

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer, Mahmut Gümüş, Igor Bondarenko et al. · The Lancet · 2021 · 799 citations

Medicine, Oncology, Pharmacology +13

Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial

Andrew B. Lassman, Stephanie L. Pugh, Tony J. C. Wang et al. · Neuro-Oncology · 2022 · 147 citations · Full text

Medicine, Oncology, Pharmacology +15

Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study

Lauren A. Byers, Dmitry Bentsion, Steven Gans et al. · Clinical Cancer Research · 2021 · 75 citations · Full text

Medicine, Oncology, Pharmacology +14

A Phase III Randomized Equivalence Study of Biosimilar Filgrastim versus Amgen Filgrastim in Patients Receiving Myelosuppressive Chemotherapy for Breast Cancer

Cornelius F. Waller, Semiglazov Vf, Sergei Tjulandin et al. · Oncology Research and Treatment · 2010 · 57 citations

Medicine, Oncology, Pharmacology +16

LBA52 EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%

Ahmet Sezer, Mahmut Gümüş, Igor Bondarenko et al. · Annals of Oncology · 2020 · 27 citations · Full text

Medicine, Oncology, Pharmacology +17